Amphotericin B deoxycholate
Phase 3Small molecule
Merck & Co.Amphotericin B deoxycholate is one of 13 small molecule programs targeting Cryptococcal Meningitis. It is currently in Phase 3.
2
Indications
13
Total Trials
1
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
11 competitors in Aspergillosis
#DrugCompanyPhaseTrials
1Vfend
PPrism Pharmaceuticals
Approved
Eraxis
VVicuron Pharmaceuticals
Approved
Mycamine
BBaxter Healthcare Corporation
Approved
Noxafil
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Sporanox
SSebela Pharmaceuticals Development LLC
Approved
Abelcet
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Cancidas
FFresenius Kabi Taiwan Ltd.
Approved
Versed
CConrado Roberto Hoffmann Filho
Approved
Diflucan
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Amphotericin B deoxycholate
Merck & Co.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Visceral Leishmaniasis5 trials
Single Infusion of Liposomal Amphotericin B in Indian Visceral Leishmaniasis
Completed·—·Phase 3·NCT00628719·400 enrolled
Show 2 more trials
Combination Therapy in Indian Visceral Leishmaniasis
Completed·—·Phase 3·NCT00523965·624 enrolled
Candidiasis2 trials
Aspergillosis2 trials
Comparison of Voriconazole and Amphotericin B in Treating Patients With Aspergillosis
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00003031·212 enrolled
Cryptococcal Meningitis2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Amphotericin B deoxycholate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company